Haruko Iwase

High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway

Kosuke Yoshihara, Tatsuhiko Tsunoda, Daichi Shigemizu et al. · Clinical Cancer Research · 2012 · 196 citations · Full text

Adjuvant Chemotherapy for Stage I Clear Cell Carcinoma of the Ovary

Toshio Takada, Haruko Iwase, Chiaki Iitsuka et al. · International Journal of Gynecological Cancer · 2012 · 45 citations

Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients

Haruko Iwase, Toshio Takada, Chiaki Iitsuka et al. · Journal of Gynecologic Oncology · 2015 · 32 citations · Full text

The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1)

Ryusuke Murakami, Noriomi Matsumura, Hirofumi Michimae et al. · Gynecologic Oncology · 2019 · 23 citations

Mesenchymal Transition Subtype, Malignant Disease, Dense Taxane Chemotherapy +8

Assessment of transposed ovarian movement: how much of a safety margin should be added during pelvic radiotherapy?

Itaru Soda, Hiromichi Ishiyama, Shigemitsu Ono et al. · Journal of Radiation Research · 2015 · 16 citations · Full text

Surgical Oncology, Pelvic Radiotherapy, Ovarian Transposition +23